Lamivudine-13C,15N3

Lamivudine-13C,15N3 (BCH-189-13C,15N3) is 13C and 15N labeled Lamivudine. Lamivudine (BCH-189) is an orally active nucleoside reverse transcriptase inhibitor (NRTI) . Lamivudine can inhibit HIV reverse transcriptase 1/2 and also the reverse transcriptase of hepatitis B virus. Lamivudine salicylate can penetrate the CNS[1][2].

Product Specifications

CAS Number

[1261394-64-2]

Product Name Alternative

BCH-189-13C,15N3

UNSPSC

12352005

Target

HBV; HIV; Isotope-Labeled Compounds; Reverse Transcriptase

Related Pathways

Anti-infection; Others

Applications

COVID-19-anti-virus

Field of Research

Infection; Cancer

Smiles

O=[13C]1[15N](C=CC([15NH2])=[15N]1)[C@H]2O[C@H](SC2)CO

Molecular Formula

C7 13CH11 15N3O3S

Molecular Weight

233.23

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Colledge D, et al. Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro. Hepatology. 1997 Jul;26 (1) :216-25. |[3]Olaniyan LW, et al. Lamivudine-Induced Liver Injury. Open Access Maced J Med Sci. 2015 Dec 15;3 (4) :545-50. |[4]Mdanda S, et al. Zidovudine and Lamivudine as Potential Agents to Combat HIV-Associated Neurocognitive Disorder. Assay Drug Dev Technol. 2019 Oct;17 (7) :322-329.